强化流感疫苗对65岁及以上人群有效性的影响，丹麦，2024/25流感季截至2025年3月4日
Enhanced influenza vaccines impact effectiveness in individuals aged 65 years and older, Denmark, 2024/25 influenza season up to 4 March 2025.
作者信息
Emborg Hanne-Dorthe, Valentiner-Branth Palle, Trebbien Ramona, Bolt Botnen Amanda, Grove Krause Tyra, Søborg Bolette
机构信息
Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark.
Department of Virology and Microbiological Preparedness, Statens Serum Institut, Copenhagen, Denmark.
出版信息
Euro Surveill. 2025 Mar;30(12). doi: 10.2807/1560-7917.ES.2025.30.12.2500174.
During the 2024/25 influenza season, enhanced and standard-dose influenza vaccines were available for individuals aged 65 and older. Compared with the standard-dose quadrivalent influenza vaccine (QIV), the adjuvanted QIV was significantly more effective, with an overall vaccine effectiveness (VE) of 48% (95% CI: 42-52) vs 33% (95% CI: 24-41) when considering both non-hospitalised and hospitalised patients. The high-dose QIV demonstrated similar effectiveness to the adjuvanted QIV. These findings support the inclusion of enhanced influenza vaccines in future vaccination programmes.
在2024/25流感季节，65岁及以上人群可接种强化剂量和标准剂量的流感疫苗。与标准剂量四价流感疫苗（QIV）相比，佐剂QIV的效果显著更佳，在考虑非住院和住院患者时，总体疫苗效力（VE）为48%（95%CI：42-52），而标准剂量QIV为33%（95%CI：24-41）。高剂量QIV显示出与佐剂QIV相似的效力。这些发现支持在未来的疫苗接种计划中纳入强化流感疫苗。
Zotero 插件